Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

TSX:EDT - Post by User

Spectral Medical Inc > 9’er 9’er post - slight correction.

<< Previous

Bullboard Posts

Next >>

Post by mercedesmanon Aug 03, 2024 5:20pm

236 Views

Post# 36163501

9’er 9’er post - slight correction.

Slide 15 seems to show end dates using a worst case of .19 patients per site per month ( or about 4.5/mo for all sites combined) and a best case of .29 per site per month ( or about 6.67/month for all sites combined - appears to be the 2024 YTD totals )

Lately we have been averaging .39 patients per site per month based on a now active 23 sites. (this is based on a pair-o-nines or a niner-niner, or the "Wayne Gretzky", 9/23 = .3913)

And ... the momentum is still building !

As we know, the closer we are to the trial end, the more ethusiastic & diligent are the trial research personnel.

MM

<< Previous

Bullboard Posts

Next >>

Fobi AI responds to cease trade order, filing delay “disappointing”